Earnings Releases·Oct 29, 2026, 7:03 AM ET

Eli Lilly and Company — Third Quarter 2026 Earnings Summary

Q3 2026 worldwide revenue surged 39% year-over-year to $24.4 billion, driven by a 53% volume increase that partially offset a 15% decline in realized prices; reported net income and EPS both rose 16% to $6.5 billion and $7.22, respectively.
Full-year 2026 guidance was raised significantly, with revenue guidance increased by $5.5 billion to $91.0–$92.0 billion and underlying non-GAAP EPS guidance raised by $4.07 at the midpoint to $35.00–$36.00.
Key product lines demonstrated robust growth, with Mounjaro revenue up 65% to $10.7 billion and Zepbound up 49% to $5.4 billion, while Immunology, Oncology, and Neuroscience therapeutic areas collectively grew 100% year-over-year.
Strategic developments included the completion of acquisitions for AtaiBeckley and Merida Biosciences, the initiation of Phase 3 trials for EloraTZP, and the expansion of manufacturing capacity in Texas and Virginia.
Management noted pricing pressures from global realized price decreases and significant $4.2 billion in acquired IPR&D charges, though dividends per share increased 15% to $1.73.